Physician profile
David A Suber
NPI 1477546323
$640.44
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $143 · 2021: $334 · 2024: $163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $141 · Education: $22.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $140.82 |
| Education | $22.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $199.28 | 2020-2024 | Zeposia |
| Lilly USA, LLC | $40.42 | 2020-2021 | |
| Biogen, INC. | $38.88 | 2021 | |
| Genzyme Corporation | $35.77 | 2021 | |
| Pfizer INC. | $28.69 | 2021 | |
| Abbvie INC. | $27.45 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $26.52 | 2021 | |
| Allergan, INC. | $26.50 | 2020 | |
| Ge Healthcare | $23.70 | 2020 | |
| Emd Serono, INC. | $22.60 | 2021 | |
| Tg Therapeutics, INC. | $22.17 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $17.41 | 2020 | |
| Banner Life Sciences, LLC | $17.40 | 2021 | |
| Strongbridge US INC. | $15.94 | 2020 | |
| Ucb, INC. | $15.45 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $15.19 | 2021 | |
| Upsher-Smith Laboratories LLC | $14.37 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.99 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $13.93 | 2021 | |
| Sk Life Science, INC. | $13.36 | 2020 | |
| Alexion Pharmaceuticals, INC. | $11.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Suber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.